Repetitive Trans-cranial Magnetic Stimulation of the Motor Cortex in Fibromyalgia: A Study Evaluating the Clinical Efficiency and the Metabolic Correlate in 18FDG-PET

Assistance Publique Hopitaux De Marseille38 enrolled

Overview

Fibromyalgia (FM) syndrome is a chronic pain condition.Repetitive trans-cranial magnetic stimulation (rTMS) was thus suggested in this indication.

We recently demonstrated that these patients exhibit significant perfusion abnormalities in regions of the brain known to be involved in sensory and affective-attentional dimensions of pain processing. These results, in agreement with previous functional magnetic resonance imaging reports, confirm the hypothesis of central sensitization, which provides the rationale for prescription of centrally acting analgesic agents in patients with severe FM.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Fibromyalgia

Interventions

Transcranial stimulationOTHER

Stimulation to white

Transcranial stimulationOTHER

Repetitive transcranial magnetic stimulation (rTMS)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female or male patient, aged from 18 to 65 years * Patient presenting a primary fibromyalgia answering the criteria of the ACR * At present painful patient with a digital echelle of the briefing inventory bread superior or equal to 4/10 * Patient presenting a stable treatment since at least 1 less Exclusion Criteria: * Patient minor * pregnant woman * women in age to procreate without contraception * patient deprived of freedom further to a court or administrative order * patient presenting a secondary fibromyalgia

Locations (1)

Hôpital de la Timone- Service dCentral de Biophysique et de Médecine Nucléaire

Marseille, France

Outcomes

Primary Outcomes

Analgesic efficiency

Time frame: 36 months

Secondary Outcomes

Additional evaluation of the pain

Time frame: 36 months

Evaluation of the quality of life

Time frame: 36 months

Evaluation of the tolerance of the treatment

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.